Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Nilotinib (AMN-107)
Cat No.
CEI-0267
Description
Nilotinib (AMN-107) can inhibit Bcr-Abl with IC50 of 30 nM.
Alias
Tasigna
CAS No.
641571-10-0
Molecular Weight
529.52
Purity
>99%
Storage
2 years at -20centigrade Powder
Synonyms
Tasigna
Targets
Bcr-Abl
Molecular Formula
C28H22F3N7O
Chemical Name
4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide
Solubility
DMSO 36 mg/mL Water
In vitro
Nilotinib(AMN-107) is a novel tyrosine kinase inhibitor targeting KIT (CD117), PDGFR and BCR-ABL and inhibiting the proliferation of both imatinib-sensitive and imatinib-resistant cells in vitro. AMN-107, which is more potent than imatinib, can inhibit the proliferation of haematopoietic cells expressing the mutants in Ph+ CML and acute lymphoblastic leukaemia with IC50 of 12 nM, approximately. For several imatinib-resistant Bcr-Abl mutants expect T3151, AMN-107 can effective against them.
In vivo
In mice transduced with Bcr-Abl, AMN-107 reduced mortality and tumour burden. In mice transduced with the E255V imatinib-resistant mutant of Bcr-Abl, AMN-107 delayed the onset of leukaemia.
Download
Download Datasheet